AIM Pharmaceutical International Limited

AIM Pharma is a biotechnology company focusing on the treatment of neurodegenerative diseases. Its flagship candidate, AIM-01-PD, is a novel small-molecule drug derived from Alpinia oxyphylla, for the treatment of mild to moderate Parkinson’s Disease and its complications. AIM-01-PD has a novel mechanism of action and has shown multiple neuroprotective effects in preclinical studies, effectively alleviating neuronal loss and dopamine reduction in the brain. The company has submitted an investigational new drug application in China, aiming to initiate Phase 1 clinical trials in 2025. Powered by its original, globally patented LifeChip Technology Platform, AIM Pharma revolutionises drug discovery by efficiently identifying safe and effective lead compounds
by integrating unique zebrafish disease models, highthroughput drug screening, and advanced drug discovery strategies. Furthermore, AIM Pharma has established strategic partnerships worldwide, with a business model designed to maximise efficiency. It focuses on R&D while leveraging partnerships for manufacturing, distribution, and marketing, deriving revenue from licensing fees and royalties.

Team Member(s)

Prof. Lee Ming-yuen, Simon (Department of Food Science and Nutrition)

CAO Chen, Logan

ZHAO Chen, Grace

KUOK Kit-Ieng, Jess